Fan Yang1, Piers Dawes2, Iracema Leroi3, Brenda Gannon4. 1. Manchester Centre for Health Economics, University of Manchester, Manchester, UK. 2. Manchester Centre for Audiology and Deafness, University of Manchester, Manchester, UK. 3. Institute of Brain, Behaviour, and Mental Health, University of Manchester, Manchester, UK. 4. Centre for Business and Economics of Health, University of Queensland, Brisbane, Australia.
Abstract
OBJECTIVE: Knowledge is limited about the standardised instruments used to collect resource use and quality of life data alongside trials of dementia interventions. This review aimed to identify the trials using such instruments in order to guide the design of future trial-based cost-effectiveness studies. METHODS: In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement, this review examined all original, peer-reviewed research in major databases and general searches published until June 2017, including randomised clinical trials, pilot studies, or feasibility studies about interventions for older adults with dementia or cognitive impairment. RESULTS: Forty-one studies were identified. Only 8 collected the resource use data using adapted Client Service Receipt Inventory (CSRI), Resource Use Inventory (RUI), cost diary, or study-specific questionnaire. Quality of life was assessed using a wide range of instruments. The most frequently used dementia-specific instrument was Quality of Life in Alzheimer's Disease (QOL-AD) and Dementia Quality of Life questionnaire (DEMQOL). Among the generic measures, EuroQol 5-dimentison (EQ-5D) was mostly used to collect health utility data, and Short Form surveys (SF-36 or SF-12) were widely to measure general health. CONCLUSIONS: Several useful resource use and quality of life measurement instruments have been identified by this review. For resource use, CSRI was mostly used, but no studies have used Resource Utilisation in Dementia (RUD); for quality of life, we recommend the inclusion of dementia-specific DEMQOL, generic SF-12, and health utility EQ-5D-5L, based on both self-report and proxy-report.
OBJECTIVE: Knowledge is limited about the standardised instruments used to collect resource use and quality of life data alongside trials of dementia interventions. This review aimed to identify the trials using such instruments in order to guide the design of future trial-based cost-effectiveness studies. METHODS: In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement, this review examined all original, peer-reviewed research in major databases and general searches published until June 2017, including randomised clinical trials, pilot studies, or feasibility studies about interventions for older adults with dementia or cognitive impairment. RESULTS: Forty-one studies were identified. Only 8 collected the resource use data using adapted Client Service Receipt Inventory (CSRI), Resource Use Inventory (RUI), cost diary, or study-specific questionnaire. Quality of life was assessed using a wide range of instruments. The most frequently used dementia-specific instrument was Quality of Life in Alzheimer's Disease (QOL-AD) and Dementia Quality of Life questionnaire (DEMQOL). Among the generic measures, EuroQol 5-dimentison (EQ-5D) was mostly used to collect health utility data, and Short Form surveys (SF-36 or SF-12) were widely to measure general health. CONCLUSIONS: Several useful resource use and quality of life measurement instruments have been identified by this review. For resource use, CSRI was mostly used, but no studies have used Resource Utilisation in Dementia (RUD); for quality of life, we recommend the inclusion of dementia-specific DEMQOL, generic SF-12, and health utility EQ-5D-5L, based on both self-report and proxy-report.
Authors: Jo Ellen Wilson; Matthew F Mart; Colm Cunningham; Yahya Shehabi; Timothy D Girard; Alasdair M J MacLullich; Arjen J C Slooter; E Wesley Ely Journal: Nat Rev Dis Primers Date: 2020-11-12 Impact factor: 65.038
Authors: Youssef H El-Hayek; Ryan E Wiley; Charles P Khoury; Ritesh P Daya; Clive Ballard; Alison R Evans; Michael Karran; José Luis Molinuevo; Matthew Norton; Alireza Atri Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Alys W Griffiths; Sarah J Smith; Adam Martin; David Meads; Rachael Kelley; Claire A Surr Journal: Qual Life Res Date: 2019-10-23 Impact factor: 4.147
Authors: Álvaro González-Domínguez; Francisco Visiedo; Jesus Domínguez-Riscart; Beatriz Ruiz-Mateos; Ana Saez-Benito; Alfonso M Lechuga-Sancho; Rosa María Mateos Journal: Antioxidants (Basel) Date: 2021-02-05